Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416995
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-13
Brief Title:
Serum Vasohibin Cardiotrophin Endocan Perinatal Outcomes
Sponsor:
Umraniye Education and Research Hospital
Organization:
Umraniye Education and Research Hospital
Study Overview
Official Title:
Investigation of First Trimester Serum Vasohibin-1 Vasohibin-2 Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigation of the relationship between maternal serum vasohibin-1 vasohibin-2 cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes
Detailed Description:
Previous animal model studies in the literature have shown that vasohibin-1 released in endothelial cells inhibits angiogenesis while vasohibin-2 stimulates angiogenesis Additionally immunohistochemical studies have shown that vasohibin-2 plays a role in the cellular fusion of trophoblasts in the placenta to form syncytiotrophoblasts
Studies in the literature have shown that cardiotrophin-1 is expressed in cardiac myocytes and vascular endothelial cells and stimulates the synthesis and secretion of endothelin-1 in endothelial cells through the gp130 signaling pathway Since endothelin 1 plays an important role in the regulation of vascular tone cardiotrophin-1 can be considered to act as an endothelium-derived biological factor possibly involved in the regulation of vascular tone under normal physiological conditions or secondary to pathological processes
Studies in the literature have shown that maternal serum endocan levels are higher in pregnant women whose pregnancies were complicated by preeclampsia than in normotensive pregnant women and that the endocan molecule may be effective in the etiopathogenesis of preeclampsia especially if it develops early
In the light of this above-mentioned information we aim to investigate whether serum vasohibin-1 vasohibin-2 cardiotrophin-1 and endocan concentrations measured during the 11th to 14th weeks of pregnancy can be used to predict preeclampsia gestational hypertension fetal growth restriction preterm birth and gestational diabetes mellitus
Studies in the literature have shown that cardiotrophin-1 is expressed in cardiac myocytes and vascular endothelial cells and stimulates the synthesis and secretion of endothelin-1 in endothelial cells through the gp130 signaling pathway Since endothelin 1 plays an important role in the regulation of vascular tone cardiotrophin-1 can be considered to act as an endothelium-derived biological factor possibly involved in the regulation of vascular tone under normal physiological conditions or secondary to pathological processes
Studies in the literature have shown that maternal serum endocan levels are higher in pregnant women whose pregnancies were complicated by preeclampsia than in normotensive pregnant women and that the endocan molecule may be effective in the etiopathogenesis of preeclampsia especially if it develops early
In the light of this above-mentioned information we aim to investigate whether serum vasohibin-1 vasohibin-2 cardiotrophin-1 and endocan concentrations measured during the 11th to 14th weeks of pregnancy can be used to predict preeclampsia gestational hypertension fetal growth restriction preterm birth and gestational diabetes mellitus
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None